Literature DB >> 26492937

Discovery of Chemical Inhibitors of Human Bromodomains.

Guangtao Zhang1, Steven G Smith1, Ming-Ming Zhou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26492937     DOI： 10.1021/acs.chemrev.5b00205

Source DB:  PubMed          Journal:  Chem Rev        ISSN： 0009-2665            Impact factor:   60.622


× No keyword cloud information.
  34 in total

1.  Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Authors:  Stuart W Ember; Que T Lambert; Norbert Berndt; Steven Gunawan; Muhammad Ayaz; Marilena Tauro; Jin-Yi Zhu; Paula J Cranfill; Patricia Greninger; Conor C Lynch; Cyril H Benes; Harshani R Lawrence; Gary W Reuther; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  Mol Cancer Ther       Date:  2017-03-23       Impact factor: 6.261

2.  Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.

Authors:  Forest H Andrews; Alok R Singh; Shweta Joshi; Cassandra A Smith; Guillermo A Morales; Joseph R Garlich; Donald L Durden; Tatiana G Kutateladze
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

3.  Binding Motifs in the CBP Bromodomain: An Analysis of 20 Crystal Structures of Complexes with Small Molecules.

Authors:  Jian Zhu; Jing Dong; Laurent Batiste; Andrea Unzue; Aymeric Dolbois; Vlad Pascanu; Paweł Śledź; Cristina Nevado; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2018-08-08       Impact factor: 4.345

4.  BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.

Authors:  Alex M Ayoub; Laura M L Hawk; Ryan J Herzig; Jiewei Jiang; Andrea J Wisniewski; Clifford T Gee; Peiliang Zhao; Jin-Yi Zhu; Norbert Berndt; Nana K Offei-Addo; Thomas G Scott; Jun Qi; James E Bradner; Timothy R Ward; Ernst Schönbrunn; Gunda I Georg; William C K Pomerantz
Journal:  J Med Chem       Date:  2017-06-07       Impact factor: 7.446

5.  Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-a]pyrazin-8(7H)-one as Novel BRD4 Inhibitors.

Authors:  Yifei Yang; Pan Chen; Leilei Zhao; Fangqing Zhang; Huibin Zhang; Jinpei Zhou
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

6.  Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.

Authors:  Phillip P Sharp; Jean-Marc Garnier; Tamas Hatfaludi; Zhen Xu; David Segal; Kate E Jarman; Hélène Jousset; Alexandra Garnham; John T Feutrill; Anthony Cuzzupe; Peter Hall; Scott Taylor; Carl R Walkley; Dean Tyler; Mark A Dawson; Peter Czabotar; Andrew F Wilks; Stefan Glaser; David C S Huang; Christopher J Burns
Journal:  ACS Med Chem Lett       Date:  2017-11-14       Impact factor: 4.345

7.  Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.

Authors:  Zhiqing Liu; Haiying Chen; Pingyuan Wang; Yi Li; Eric A Wold; Paul G Leonard; Sarah Joseph; Allan R Brasier; Bing Tian; Jia Zhou
Journal:  J Med Chem       Date:  2020-04-22       Impact factor: 7.446

Review 8.  Phospho-BRD4: transcription plasticity and drug targeting.

Authors:  Cheng-Ming Chiang
Journal:  Drug Discov Today Technol       Date:  2016-07-18

9.  Double duty: ZMYND8 in the DNA damage response and cancer.

Authors:  Fade Gong; Kyle M Miller
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

Review 10.  Involvement of Brd4 in different steps of the papillomavirus life cycle.

Authors:  Thomas Iftner; Juliane Haedicke-Jarboui; Shwu-Yuan Wu; Cheng-Ming Chiang
Journal:  Virus Res       Date:  2016-12-10       Impact factor: 3.303
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.